US 11,945,841 B2
Headless hemagglutin influenza vaccine
Baozhong Wang, Duluth, GA (US); and Lei Deng, Atlanta, GA (US)
Assigned to Gerogia State University Research Foundation, Inc., Atlanta, GA (US)
Appl. No. 16/649,905
Filed by Georgia State University Research Foundation, Inc., Atlanta, GA (US)
PCT Filed Oct. 4, 2018, PCT No. PCT/US2018/054335
§ 371(c)(1), (2) Date Mar. 23, 2020,
PCT Pub. No. WO2019/070955, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/567,936, filed on Oct. 4, 2017.
Prior Publication US 2020/0247852 A1, Aug. 6, 2020
Int. Cl. C07K 14/005 (2006.01); A61K 9/51 (2006.01); A61K 39/145 (2006.01); C12N 7/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 9/51 (2013.01); A61K 39/145 (2013.01); C12N 7/00 (2013.01); C07K 2319/02 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16123 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16222 (2013.01); C12N 2760/16223 (2013.01); C12N 2760/16234 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A nanoparticle formed by crosslinking a fusion protein with a crosslinking agent and/or desolvating the fusion protein with a desolvating agent, wherein the fusion protein comprises a series of 2 to 8 influenza virus matrix protein 2 extracellular (M2e) domains, wherein the series of 2 to 8 influenza virus M2e domains is linked to a multimerization domain, wherein the fusion protein further comprises influenza neuraminidase (NA) protein linked to the multimerization domain.